Patients with myelodysplastic syndrome (MDS) commonly present with pancytopenia, suggesting that the marrow stroma fails to support the growth of both malignant and normal stem cells. We therefore retrospectively analyzed the duration to engraftment of neutrophils (X0.5 Â 10 9 /l and X1.0 Â 10 9 /l) and platelets (X20 and X50 Â 10 9 /l) in 37 MDS patients and 42 patients suffering from primary AML, following allogeneic SCT. A significantly shorter time to engraftment was documented in AML as compared to MDS patients in all four parameters. These results held true even when we subgrouped the patients according to gender, age (50 years being the cutoff age between young and elderly patients), patient-donor relationship, donor match and intensity of conditioning. To the best of our knowledge, this is the first time that such a comparison has been made. We suggest that the longer duration of post transplant pancytopenia that is frequently observed in MDS patients may also influence post transplant outcome.
Introduction
Normal hematopoiesis depends on the balanced interplay of hematopoietic stem cells and the cells and molecules that form part of the microenvironment in which blood cell production takes place. 1 Myelodysplastic syndrome (MDS) is a distinct, albeit heterogeneous, group of acquired clonally hematopoietic pathologies characterized by ineffective hematopoiesis and refractory cytopenias that frequently result in overt leukemia. [2] [3] [4] The incidence of these disorders has increased significantly over the last decades, most commonly among elderly individuals. 5 Paradoxically, hematopoietic cells in BM of MDS patients frequently feature high proliferative capacity, with erythroid, myeloid and megakaryocytic cells actively engaged in DNA synthesis, 6 while the peripheral blood manifests pancytopenia. The clonal nature of MDS is well documented, and genomic abnormalities, mostly deletions, are likely to be related to genomic instability or impaired DNA repair. 7, 8 Whereas undetectable chromosomal changes occur frequently in the early stages of MDS, multiple genomic abnormalities are observed during disease progression and conversion to overt leukemia. Indeed, MDS is always considered a preleukemic condition. [2] [3] [4] Nuclear fragmentation and budding cells, long recognized morphological features of MDS, have been identified as characteristics of cells undergoing apoptotic cell death. 9 In a work by Aizawa et al., 10 it was demonstrated that in at least some MDS patients, primary MDS marrow stroma cells failed to support growth of normal stem cells when these cells were cocultured. Furthermore, apoptotic changes in hematopoietic cells were frequently observed in the cocultures, and the level of CD95 expression on the hematopoietic cells seemed to be induced by the MDS stromal environment. [10] [11] [12] Compared to normal stroma, MDS-derived stroma showed fewer foci of adipocytes, more CD14 þ cells and higher levels of O À 2 . All the above suggest that MDS stroma may be functionally different from normal stroma 13 and may thus influence the fate of stem cells in this disorder.
Taking these factors into consideration, it was reasonable to assume that MDS stroma would have a negative influence on donor stem cells, which bind to this stroma after SCT; indeed, such negative influence is reflected in slow engraftment. Since the stromal microenvironment following SCT remains of host origin, 14 we hypothesized that engraftment of normal donor stem cells post-SCT might be impaired. This assumption was also raised in a report by Weber-Mzell et al., 15 where the authors speculated that support by stroma-derived cells was the reason for durable engraftment in a patient with severe aplastic anemia and two failures of previous allogeneic peripheral blood SCT. The time required to achieve engraftment of donor stem cells, as well as patient-donor chimerism status post transplantation, is included in the majority of reports dealing with transplantation of AML and MDS patients as one group. [16] [17] [18] [19] [20] Others, that evaluate each diagnosis separately, document the duration to engraftment that ranges from 6 to 17 days for AML 21, 22 and 19-20 days for MDS patients. 23, 24 However, a direct comparison between the two diagnoses has never been made. We therefore undertook a retrospective analysis of time to engraftment in patients who underwent SCT for MDS and AML. Our results appear to support our working hypothesis that engraftment of both myeloid lineage and platelets is delayed in patients with MDS as compared to patients with AML. Table 1 . Patient ages ranged from 8 to 68 (median 39.5) years and from 9 to 74 (median 42) years in the AML and MDS groups, respectively. The Karnofsky performance score ranged from 40 to 100 (median 100) in the AML group and from 50 to 100 (median 100) in the MDS group. In the AML group, 25 patients were males and 17 were females, whereas in the MDS group 28 were males and 9 were females. Subdiagnoses in the AML group were as follows: 4 patients were classified as M0, 11 as M1, 9 as M2, 2 as M3, 5 as M4 and 8 as M5. Three patients were referred to our department without a subdiagnosis. In the MDS group, 8 patients had refractory anemia (RA), 22 had refractory anemia with excess blasts (RAEB) and 7 had refractory anemia with excess blasts in transformation (RAEB-T). Approved informed consent forms were signed by all patients or their legal guardians. Chemotherapy before referral for SCT was given as follows: in the AML group, 9 patients received 1 course, 9 received 2 courses and 24 received more than 2 courses; in the MDS group, 24 patients received no prior chemotherapy; 6 received 1 course; 1 received 2 courses and 1 received more than 2 courses. Of the AML patients, 34 patients were transplanted from HLA-A, -B, -C and high resolution class II fully matched siblings; 3 patients received an allograft from a fully matched unrelated donor (MUD), nonreactive in mixed lymphocyte culture and 5 patients were transplanted from haploidentical related donors. In the MDS group, 25 patients were transplanted from HLA-A, -B, -C and high resolution class II matched siblings; 8 patients received an allograft from a MUD, nonreactive in mixed lymphocyte culture; 1 patient was transplanted from a partially mismatched related donor and 3 from partially mismatched unrelated donors. Ten patients with AML were transplanted in 1st CR, 1 in PR, 8 in 2nd CR, 14 in 1st relapse, 2 in 2nd relapse and 7 with resistant disease. Thirty-six AML patients and 31 of the MDS patients received pretransplant nonmyeloablative conditioning consisting of i.v. fludarabine 30 mg/m 2 per day for 6 days; oral busulfan 4 mg/kg per day or i.v. busulfex 3.2mg/kg per day for 2 days and antithymocytic globulin (Fresenius AG, Bad Homburg, Germany) 5 mg/kg per day for 4 days. Six AML patients with active disease (that is, relapse/resistant disease) and 6 of the MDS patients received a myeloablative regimen Longer duration to engraftment in MDS than in AML patients M Bitan et al consisting of the above protocol to which melphalan 60 mg/m 2 per day or thiotepa 5 mg/kg per day for 2 days was added. The 5 AML patients who underwent haploidentical transplantation received a T-cell depleted graft. Prior to transplantation, all patients received antibacterial prophylaxis consisting of trimethoprim/sulfamethoxazole (10 mg/kg per day) on days À8 to À2, acyclovir (500 mg/m 2 Â 3 per day) from days À8 until day þ 100 and allopurinol (300 mg per day) on days À8 to À1. Administration of trimethoprim/sulfamethoxazole twice weekly was reinstituted after recovery from neutropenia, as prophylaxis against pneumocystis carinii infection. CMV infections diagnosed by two successive positive PCRs or one positive CMV pp65 antigenemia test (from the time this technique became available in our center), were treated with gancyclovir 10 mg/kg per day. Neutropenic patients with culture-negative fever received a combination of gentamycin, cefazolin and mezlocillin or, more recently, piperacillin as firstline antibiotics. Persistent fever was treated with amikacin and ceftazidime or, more recently, with tazocin as a second-line protocol, while meropenem and vancomycin were used as third-line therapy. In cases of persistent fever that did not respond to antibiotic therapy within 5 days, amphotericin B (1 mg/kg every other day) was added, until neutropenia resolved.
Patients and methods

Patients
The number of CD34 þ cells infused in the AML patients ranged from 2.96 to 144.8 Â 10 6 (median 10.8)/kg body weight and in the MDS group from 0.54 to 62.4 Â 10 6 (median 13.75)/kg body weight. Thus, there was no significant statistical difference between the two groups of patients in terms of the CD34 þ cell doses infused (Pvalue ¼ 0.71). None of the patients included in this study were given GCSF post transplantation. GVHD prophylaxis for all patients consisted of low-dose short-term cyclosporine (CSA) 3 mg/kg i.v. daily in two doses starting on day À4. When the patients were sufficiently fit, CSA was administered orally. CSA dosage was tapered during the second or third month post transplant according to chimeric status, unless patients developed active GVHD. For cases at high risk of relapse, tapering of CSA began earlier. Acute GVHD was graded according to Glucksberg's criteria, 25 and chronic GVHD according to the International Bone Marrow Transplant Registry (IBMTR) consensus criteria. 26 Upon appearance of signs and symptoms of acute GVHD 4grade I, methylprednisolone (2 mg/kg) and CSA were administered. Patients were treated in rooms equipped with HEPA filters. All patients received a normal diet. Platelet support was administered as indicated, either because of bleeding or to maintain platelet counts 410 Â 10 9 /l. Platelet engraftment was recorded when unsupported levels reached X20 Â 10 9 and X50 Â 10 9 /l. Engraftment of neutrophils was recorded when the ANC reached X0.5 Â 10 9 and 1.0 Â 10 9 /l. To confirm engraftment, assess degree of chimerism and evaluate minimal residual disease and early relapse, patients were monitored at regular 7-10 day intervals by cytogenetic analysis, donor and host-specific DNA markers, including male and female amelogenine gene PCR bands, 27 and VNTR-PCR assay. 28 This was done only on a whole-blood basis due to the unavailability of the technique to separate leukocytes from lymphocytes, in our center.
Statistical analysis
Four time variables-number of days required to achieve ANC40.5 Â 10 9 and 41.0 Â 10 9 /l, and platelet counts 420 Â 10 9 and 50 Â 10 9 /l were analyzed as follows: (1) Univariate comparisons were made. Distributions of time variables were examined and tested for normality by means of the Kolmogorov-Smirnov test with Lilliefors Significance Correction. Our tests showed a marked departure from normality. Therefore, whenever a group, for comparison, had fewer than 30 cases, the nonparametric MannWhitney test was used. Otherwise, following Levene's test for equality of variances, the appropriate t-test was applied. Continuous explanatory variables were examined by linear quadratic and logarithmic regressions after dividing the subjects into three equal groups; (2) Age, gender and donor type interactions were examined; these were not found to be statistically significant; (3) A stepwise backward ANOVA analysis was carried out, that included all variables showing statistical significance (Po0.05) on univariate analysis. The final model presented includes the significant variables in this ANOVA after exclusion of the nonsignificant factors.
Median time and probability curves were obtained by the Kaplan-Meier procedure and compared by means of the log-rank test.
Results
All AML and MDS patients engrafted; there were no graft failures. Furthermore, all patients in both groups survived until engraftment. To assess differences in duration to engraftment between the two groups, we retrospectively recorded time of ANC recovery to counts of X0.5 Â 10 9 and X1.0 Â 10 9 /l, and platelet recovery to counts of X20 Â 10 9 and X50 Â 10 9 /l. A comparison of patients in each disease category showed that time to engraftment in all four parameters was significantly shorter among the AML patients observed ( Table 2 ). The mean time to ANCX0.5 Â 10 9 and X1.0 Â 10 9 /l in the AML group was 13.6 (median 14, range 9-18) days and 15.0 (median 15, range 10-21) days, respectively, compared to 19.3 (median Table 2 Differences between time to engraftment in AML versus MDS patients /l in the AML group were achieved in a mean 10.8 (median 10.5, range 0-15) days and 13.0 (median 13, range 9-18) days, respectively, compared to 20.7 (median 17.5, range 4-65) days and 27.8 (median 23, range 11-94) days in the MDS group, respectively (P ¼ 0.02 and 0.01, respectively) (Figures 1a-d) . Analysis of time required to achieve 100% donor chimerism showed a tendency toward shorter duration in the AML group (mean time of 27 days with a range of 6-175 days) than in the MDS group (mean time of 42 days with a range of 11-273 days), but the differences were not statistically significant (P ¼ 0.10). A comparison of the probabilities of time required for AML and MDS patients to achieve 100% donor chimerism is presented in Figure 2 .
Univariate multivariate and interactions analysis A univariate analysis was made for each time variable examined in the study. Parameters for analysis included gender, age, patient-donor relationship, SCT conditioning protocol, number of CD34 þ and CD3 þ cells infused, disease status on the day of transplantation and the number of chemotherapy courses given to the patient before transplantation. Stem cell source (BM vs peripheral blood) was not included in the overall analysis since none of the AML patients had received a BM-derived graft: all received peripheral blood stem cells. No factors were found to influence neutrophil recovery (ANC X0.5 Â 10 9 and X1.0 Â 10 9 /l) on univariate analysis; therefore, no multivariate analysis was needed. However, time required for platelet recovery (X20 Â 10 9 and X50 Â 10 9 /l), patientdonor relationship, number of CD34 þ cells infused and number of chemotherapy treatments given to the recipient before transplantation, were all found to be of potential relevance. Therefore, a multivariate analysis was done of these variables, but without any statistically significant results.
Interaction analysis examined gender and age, gender and patient-donor relationship and age and patient-donor relationship, and found them not to be statistically significant for the time variables tested in the study. (Note: Two AML patients achieved full donor chimerism only on days 63 and 175, respectively, and two MDS patients achieved it only on days 88 and 273, respectively).
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Moreover, every factor that was potentially relevant was examined for interaction with every other parameter assessed in the univariate analyses, and none was found to be statistically significant.
Role of gender, age and patient-donor relationship on engraftment Two methods were used to evaluate gender role. Firstly, all AML and MDS patients were examined as one group, and differences in each time parameter to engraftment were noted between males and females. Secondly, males with AML were compared with males with MDS, and females with AML to females with MDS. As can be seen in Table 3a , no significant differences were seen in time to engraftment between males and females in the combined AML/MDS group. Values for neutrophil recovery to ANC X0.5 Â 10 9 and X1.0 Â 10 9 /l were median 15 (range 9-53) days for males and 14 (range 10-28) days for females and 16 (range 10-54) days for males and 15 (range 10-136) days for females, respectively. For platelet reconstitution to X20 Â 10 9 and X50 Â 10 (Table 3b) . To evaluate the influence of age on the engraftment parameters, we compared elderly (X51 years (see Table 4 ) at the day of transplantation) and young (o50 years at the day of transplantation) patients. In the group of young patients the median age was 32 (range 8-49) years and 33 (range 9-50) years for AML and MDS patients, respectively. In the elderly group of patients, the median age was 58 (range 51-68) years and 55 (range 51-74) years for AML and MDS patients, respectively. Among the young patients, a significantly shorter time to engraftment of all four parameters was observed in the AML group than in the MDS group. In the AML patients ANC reached X0.5 Â 10 (Table 4) . Shorter time to neutrophil recovery in the elderly AML patients did not reach statistical significance (Table 4) .
Examination of the possible influence of patient-donor relationship on engraftment in AML and MDS patients revealed that a significantly shorter time was required for all four parameters by the AML patients than by MDS patients, when the donor was related to the patient. In the AML group, ANC achieved X0.5 Â 10 9 /l at a median 14 (range 9-18) days and X1.0 Â 10 9 /l at a median 15 (range 10-21) days, while platelets reachedX20 Â 10 (Table 5) .
Role of pretransplant conditioning on engraftment
Since pretransplant conditioning may affect engraftment, we attempted to document differences in time to engraftment according to specific conditioning protocols. However, due to the many different protocols used for transplanting the patients in both groups over the years, Longer duration to engraftment in MDS than in AML patients M Bitan et al /l parameter the median time was 33 (range 21-94) days and 15 (range 11-71) days in the BM and PBSC subgroups, respectively (P-value ¼ 0.02).
Discussion
One of the hallmarks of MDS is stromal abnormalities. 11, 13 The lack of good matrix support of the BM stem cells possibly contributes to their maturation arrest and to the Longer duration to engraftment in MDS than in AML patients M Bitan et al clinical symptoms related to pancytopenia seen in this syndrome. 10 Since stromal cells and matrix function are deficient in MDS, it was reasonable to assume that allogeneic stem cells would engraft much less efficiently in such a microenvironment. Our data present evidence for the first time in support of this assumption. In this retrospective study we demonstrated significantly better and faster engraftment following allogeneic SCT in AML patients that did not have MDS features in their background, than in MDS patients who underwent the same procedure. One could question the relevance of making such a comparison since one group of patients was given prior chemotherapy treatment and the other was not. In our opinion, the fact that AML patients received chemotherapy prior to the BMT and MDS patients did not, does not weaken our argument; on the contrary, it strengthens it, because chemotherapy negatively influences both BM cells and stroma, 30 and in such an environment transplanted stem cells will hardly engraft, whereas in MDS patients, where the stroma has not been affected by chemotherapy, the support it can give to new stem cells is better. Clinically this should be translated into shorter time to engraftment. However, the opposite happened: not only did the absence of prior chemotherapy not help, the duration to engraftment was prolonged in the MDS patients. Therefore, it might be suggested that the stroma of MDS patients has an inherent disadvantage that is even greater than the harmful effect of prior chemotherapy, resulting in prolonged duration to engraftment in these patients. The same trend of quicker engraftment in AML patients was observed in every subgroup, although some parameters were not statistically significant. No differences were observed between males and females or between young and adult patients in any of the subgroups. In the current study we evaluated chimerism on the basis of whole white blood cells, and not separately as T cell (immunological) vs myeloid chimerism. Faster immunologically evaluated engraftment in the AML group may suggest that another mechanism supporting the role of microenviroment causes the difference in speed of myeloid cell engraftment between the two groups. Thus, future investigation is warranted to evaluate lymphoid vs myeloid engraftment, as potential factors that interfere and influence engraftment in AML and MDS patients. Duration of neutropenia, anemia and thrombocytopenia peritransplantation has been associated with the incidence of transplant-related morbidity and mortality. 31 Evaluating the differences in the MDS group between BM-and PBSCderived reconstitution demonstrated significantly better engraftment of platelets in the PBSC subgroup. This may Longer duration to engraftment in MDS than in AML patients M Bitan et al cause confusion in a comparative analysis with the AML group. Nevertheless, when we compared the MDS PBSC subgroup, where time to engraftment was shorter and more like the AML group, with the AML PBSC subgroup, time to engraftment was still significantly shorter among the AML patients (Table 7) . Facilitating hematopoietic reconstitution has always been a major goal in the setting of SCT. This study underlines the importance of the role of microenvironment in hematopoietic reconstitution. Unfortunately, until recently, no methods were available for improving or changing the BM microenvironment. Based on recent investigations in our laboratory, it seems that BM cells in conjunction with demineralized bone matrix (DBM) may generate donor-derived BM microenvironment. 32 Whether or not the use of DBM together with stem cells administered intraosseously will improve stem cell reconstitution, remains to be investigated. At this time, our observations are only intended to draw the attention of the treating physician to the potentially more dangerous course of transplantation and poor outcome in patients with MDS, and the need to prevent complications that may develop because of possible slower and less efficient hematopoietic reconstitution.
